如果患者服用二甲双胍、外加改善饮食和运动都不能控制住血糖水平,指引建议他们要另外再服用一种糖尿病药物,可以是默克公司(Merck & Co.)生产的西他列廷武田制药(Takeda Pharmaceuticals Co.)的艾可拓、诺和诺德(NovoNordisk)出产的利拉鲁口或赛诺菲 (Sanofi)的胰岛素药物来得时。
With hardly any trials comparing these drugs against each other on long-term benefits, the new diabetes guidelines urge doctors and patients to discuss the pros and cons of each drug. The Mayo Clinic, for instance, has developed an online tool for patients that takes account of such factors as weight change, cost, low blood-sugar risk, blood-testing requirements and side effects. Patients for whom weight gain is a concern─and that's the leading worry among diabetics, according to Mayo's Dr. Montori─may steer clear of drugs where that is an important side effect.
由于几乎没有什么试验将这些药物的长期药效进行比较,新指引建议医生和病人要讨论各种药物的利与弊。比如说,梅奥诊所开发了一个可让患者记录体重变化、费用、低血糖风险、验血要求以及副作用等因素的在线工具。该医院的蒙托里医生称,担心体重增加问题的患者(这也是糖尿病患者最大的担忧)可能要远离主要副作用就是增加体重的药物。
Typically, many diabetics progress through three or four treatment tiers, ultimately adding insulin injections to help control their blood sugar. Researchers at UT Southwestern Medical Center argue that such a graduated treatment strategy does little to change the disease process and means that patients' own insulin-producing beta cells remain continuously exposed to high blood sugar.
【糖尿病治疗新策略】相关文章:
★ 全球氦气供应短缺
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15